GleamWall
中文EN

CVSI CV Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1510964 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-12.9%
TTM net income YoY-16.2%
TTM EPS YoY—
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—

Margins

Gross margin49.5%
Operating margin-2.5%
Net margin-13.7%
FCF margin-1.5%
EBITDA margin-1.8%

Returns

ROE-90.1%
ROA-25.6%
ROIC (approx.)-12.3%
Asset turnover1.86x

Leverage & solvency

Liabilities / assets64.7%
Debt / equity0.00x
Current ratio1.18x
Interest coverage-1.42x

Cash quality & payout

Operating cash flow / net income0.10x
Accruals ratio-23.0%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$3.03M$2.98M$3.19M$3.31M$3.26M$3.62M$3.61M$3.88M
Cost of revenue$1.51M$1.53M$1.63M$1.64M$1.68M$1.78M$1.95M$2.21M
Gross profit$1.51M$1.45M$1.56M$1.67M$1.58M$1.84M$1.66M$1.68M
R&D expense$19,000$18,000$18,000$18,000$24,000$50,000$30,000$25,000
SG&A expense$1.62M$1.73M$1.86M$1.73M$1.83M$1.93M$2.14M$2.30M
Operating income$377,000-$301,000-$318,000-$75,000-$275,000-$131,000$11,000-$646,000
Interest expense$0$1,000$93,000$129,000$107,000$130,000$151,000$94,000
Pretax income-$93,000-$770,000-$643,000-$204,000-$382,000-$261,000-$102,000-$740,000
Income tax$0$5,000$0$2,000$0$0$7,000-$14,000
Net income-$93,000-$775,000-$643,000-$206,000-$382,000-$261,000-$109,000-$726,000
EBITDA$400,000-$279,000-$295,000-$54,000-$244,000-$73,000$93,000-$532,000
EPS (basic)0.000.000.00—0.000.000.00—
EPS (diluted)0.000.000.00—0.000.000.00—
Weighted avg. shares (diluted)226.10M205.09M186.92M—184.26M184.26M184.26M—
Balance sheet
Cash & equivalents$308,000$266,000$309,000$278,000$381,000$886,000$812,000$454,000
Receivables$346,000$348,000$391,000$402,000$405,000$545,000$430,000$522,000
Inventory$3.96M$3.96M$3.90M$4.09M$4.08M$4.22M$4.37M$4.90M
Current assets$4.89M$4.88M$5.00M$5.13M$5.10M$5.94M$5.96M$6.24M
PP&E, net$302,000$319,000$329,000$344,000$349,000$363,000$364,000$399,000
Goodwill$990,000$999,000$1.00M$1.01M$1.01M$1.01M$988,000$971,000
Intangibles$55,000$62,000$68,000$76,000$82,000$88,000$90,000$93,000
Total assets$6.43M$6.52M$6.72M$6.96M$7.00M$7.95M$7.76M$7.93M
Current liabilities$4.15M$4.94M$5.18M$5.00M$4.79M$5.71M$5.25M$6.11M
Short-term debt$0$18,000$72,000$1.26M$451,000$1.02M$770,000$677,000
Long-term debt$0$0$0$387,000$504,000$208,000$498,000$0
Total debt$0$18,000$72,000$1.65M$955,000$1.23M$1.27M$677,000
Total liabilities$4.16M$4.95M$5.22M$5.49M$5.46M$6.15M$5.87M$6.13M
Shareholders' equity$2.27M$1.57M$1.50M$1.47M$1.54M$1.80M$1.89M$1.79M
Net debt-$308,000-$248,000-$237,000$1.37M$574,000$345,000$456,000$223,000
Shares outstanding235.69M213.12M193.46M184.26M184.26M184.26M184.26M184.26M
Cash flow statement
Operating cash flow$63,000$20,000$101,000-$354,000-$259,000$287,000-$81,000-$164,000
Capital expenditure$0$7,000$3,000$9,000$11,000$49,000$40,000$18,000
Free cash flow$63,000$13,000$98,000-$363,000-$270,000$238,000-$121,000-$182,000
Investing cash flow$0-$7,000-$3,000-$9,000-$11,000-$49,000-$40,000-$22,000
Financing cash flow-$18,000-$54,000-$68,000$258,000-$234,000-$167,000$480,000-$335,000
Depreciation & amortization$23,000$22,000$23,000$21,000$31,000$58,000$82,000$114,000
Stock-based compensation$132,000$148,000$148,000$123,000$124,000$132,000$118,000$104,000

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.